NCT03962543 2026-04-08ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 3 FDA
NCT01347866 2018-10-29Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced CancerPfizerPhase 1 Terminated105 enrolled 64 charts